Valone F H, Friedman M A, Wittlinger P S, Drakes T, Eisenberg P D, Malec M, Hannigan J F, Brown B W
University of California, San Francisco.
J Clin Oncol. 1989 Oct;7(10):1427-36. doi: 10.1200/JCO.1989.7.10.1427.
We compared the effectiveness of fluorouracil (5-FU) alone (arm A), high-dose leucovorin plus 5-FU (arm B), and sequential methotrexate, 5-FU, and leucovorin (arm C) for treatment of patients with advanced colorectal carcinomas who had not received prior chemotherapy. Arm A consisted of infusions of 5-FU at 12 mg/kg/d intravenously (IV) for 5 days followed by weekly infusions of 5-FU at 15 mg/kg; arm B consisted of leucovorin infusions at 200 mg/m2/d IV plus infusions of 5-FU at 400 mg/m2/d IV on days 1 through 5 of a 28-day cycle; arm C consisted of methotrexate at 50 mg/m2 orally every 6 hours for five doses followed by infusions of 5-FU, 500 mg/m2 IV, and leucovorin, 10 mg/m2 orally, every 6 hours for five doses every other week. A total of 265 patients were entered into the trial, of whom 249 (94%) were fully evaluable. The objective response rate (complete [CR] plus partial [PR] responses) was 17.3% on arm A, 18.8% on arm B, and 19.8% on arm C (log-rank test, P greater than .4). The median time to failure was 138 days on arm A, 166 days on arm B, and 182 days on arm C (log-rank test, P values of arm A v B = .06; arm A v arm C = .04). Median survival was 345 days on arm A, 324 days on arm B, and 356 days on arm C (log-rank test, P greater than .4). Treatment with 5-FU alone was significantly more dose intensive and more toxic than either of the experimental combinations. The rates of grade 3 or greater nonhematologic toxicity were 42.3% on arm A, 24.3% on arm B, and 14.3% on arm C. Hematologic toxicity was milder but had the same pattern. This study indicates that these regimens of high-dose leucovorin plus 5-FU and sequential methotrexate, 5-FU, and leucovorin are not more effective than is 5-FU alone for treatment of patients with colorectal carcinomas when 5-FU is administered at high-dose intensity.
我们比较了氟尿嘧啶(5-FU)单药治疗(A组)、高剂量亚叶酸钙联合5-FU治疗(B组)以及甲氨蝶呤、5-FU和亚叶酸钙序贯治疗(C组)对未接受过先前化疗的晚期结直肠癌患者的疗效。A组为静脉输注5-FU,剂量为12mg/kg/d,持续5天,随后每周静脉输注5-FU,剂量为15mg/kg;B组为在28天周期的第1至5天,静脉输注亚叶酸钙,剂量为200mg/m²/d,同时静脉输注5-FU,剂量为400mg/m²/d;C组为每6小时口服甲氨蝶呤50mg/m²,共5剂,随后每6小时静脉输注5-FU 500mg/m²和口服亚叶酸钙10mg/m²,共5剂,每隔一周重复一次。共有265例患者进入该试验,其中249例(94%)可进行全面评估。客观缓解率(完全缓解[CR]加部分缓解[PR])A组为17.3%,B组为18.8%,C组为19.8%(对数秩检验,P>0.4)。A组至疾病进展的中位时间为138天,B组为166天,C组为182天(对数秩检验,A组与B组比较P值=0.06;A组与C组比较P值=0.04)。A组的中位生存期为345天,B组为324天,C组为356天(对数秩检验,P>0.4)。单独使用5-FU治疗的剂量强度明显高于两种试验组合,毒性也更大。3级及以上非血液学毒性发生率A组为42.3%,B组为24.3%,C组为14.3%。血液学毒性较轻,但模式相同。本研究表明,当5-FU以高剂量强度给药时,高剂量亚叶酸钙联合5-FU以及甲氨蝶呤、5-FU和亚叶酸钙序贯治疗方案在治疗结直肠癌患者方面并不比单独使用5-FU更有效。